| ²é¿´: 285 | »Ø¸´: 0 | |||
jlucuixyÒø³æ (³õÈëÎÄ̳)
|
[ÇóÖú]
ÇóÖú·Ò룬Íò·Ö¸Ðл@Ò©Îï·ÖÎö
|
|
With AOAC guidance under a contract with Elanco Animal Health, a Division of Eli Lilly and Company, candidate methods have been recommended for the second set of priority compounds: nicarbazin, apramycin, and avilamycin (candidate methods for the original compounds tylosin, tilmicosin, narasin, monensin, and ractopamine were recommended in June 2009; see November/December 2010 issue of ILM for an update on these compounds). On December 7-9, 2010, at AOAC headquarters in Gaithersburg, Maryland, USA, expert review panels (ERPs) evaluated 30 of the most promising and potential candidate methods for nicarbazin, apramycin, and avilamycin analysis in animal tissues. Fitness-for-purpose statements were meticulously developed against which candidate methods were reviewed. [ Last edited by jlucuixy on 2011-5-20 at 13:34 ] |
» ²ÂÄãϲ»¶
288Çóµ÷¼Á£¬Ò»Ö¾Ô¸»ªÄÏÀí¹¤´óѧ071005
ÒѾÓÐ7È˻ظ´
304Çóµ÷¼Á
ÒѾÓÐ14È˻ظ´
Ò»Ö¾Ô¸211£¬»¯Ñ§310·Ö£¬±¾¿ÆÖصãË«·Ç£¬Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
293µ÷¼Á
ÒѾÓÐ7È˻ظ´
327Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
307Çóµ÷¼Á
ÒѾÓÐ14È˻ظ´
283·ÖÇóµ÷¼Á
ÒѾÓÐ14È˻ظ´
Ò»Ö¾Ô¸211£¬0703»¯Ñ§305·ÖÇóµ÷¼Á
ÒѾÓÐ16È˻ظ´
»·¾³×¨Ë¶µ÷¼Á
ÒѾÓÐ13È˻ظ´
338Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´














»Ø¸´´ËÂ¥